Clinical Trial

Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 6, 2022 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This project intends to perform autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE). The clinical-grade RPE will be transplanted into subretinal space to treat refractory age-related macular degeneration. The efficacy and safety of RPE transplants to treat macular degeneration will be monitored and analyzed with results from EDTRS, BCVA, OCT, ERG, microperimetry, and fluorescein angiography, before and after the treatment.
Trial Details
NCT Number NCT05445063
Lead Sponsor Beijing Tongren Hospital
Conditions Macular Degeneration
Enrollment 10 participants
Start Date 2022-08
Primary Completion 2026-07 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2022-07-06